VPTDF - Ventripoint Receives Additional Funding to Develop Next Generation of the VMS+ Whole-Heart Analysis System
(TheNewswire)
Toronto, Ontario - The Newswire -December 6, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) is pleased to announcethat Ventripoint has received additional advisory services and up to$107,000 in research and development funding from the NationalResearch Council of Canada Industrial Research Assistance Program (NRCIRAP). This new funding is in addition to the up to $120,000 that hasalready been approved.
“Ventripoint’s mission is to improve cardiacdiagnosis for everyone, worldwide and especially for children, so itis wonderful to have the support of the Government of Canada throughNRC IRAP as we push the limits of our technology to even betterperformance,’ stated Dr. George Adams, CEO of Ventripoint.
It is important for medical device companies to alwaysbe advancing their products to keep ahead of the competition and thissupport will be used to develop the next generation of the VMS+products. The Company has been working with an international committeeof cardiologists to define new measurements of heart function toimprove diagnose and patient care. The combined funding of up to$227,000 will provide Ventripoint with the resources and advisoryservices to further enhance the VMS+ system to revolutionize the wayheart analysis is performed.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.